RxDoctor Payments Data

Kimberly Koval

Adult Health · Springfield, NJNPI 1083987101

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (51.7%), consulting fees and other — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 18.5%. Among adult health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,590in general payments, 2019–2025

Across 412 payments — averaging $35.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Genentech USA, Inc.$1K
  • Janssen Scientific Affairs, LLC$1K
  • AstraZeneca$1K
  • AbbVie$831
  • Incyte Corporation$756
  • plus $6K from 54 others

What the payments were for

  • Consulting fees$3,48324%
  • Food & beverage$7,54152%
  • Education$1,3739%
  • Other$2,19315%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis57$2,706
Genentech USA, Inc.9$1,500
Janssen Scientific Affairs, LLC4$1,462
AstraZeneca(2 entities)21$1,145
AbbVie24$831
Incyte Corporation16$756
Johnson & Johnson(2 entities)26$753
Pfizer35$635
GSK26$564
Amgen10$334
Merck18$330
Pharmacosmos Therapeutics Inc.5$289
E.r. Squibb & Sons, L.L.C.10$252
Bayer8$203
Beigene USA, Inc.5$201
Seagen Inc.5$179
Rigel Pharmaceuticals, Inc.9$162
Takeda Pharmaceuticals U.S.A., Inc.7$151
Daiichi Sankyo Inc.9$150
Lilly USA, LLC8$136
Regeneron Healthcare Solutions, Inc.7$121
Taiho Oncology, Inc.6$107
Pharmaessentia USA Corporation6$101
AVEO Pharmaceuticals, Inc.1$100
Astellas Pharma US Inc5$91
Abbott3$66
ADC Therapeutics America, Inc.3$64
Mirati Therapeutics, Inc.3$61
Blueprint Medicines Corporation3$56
Array Biopharma Inc3$56
Tersera Therapeutics LLC3$50
Gilead3$49
Stemline Therapeutics Inc.3$49
Servier Pharmaceuticals LLC3$48
Genmab U.S., Inc.3$47
Foundation Medicine, Inc.1$46
Adaptive Biotechnologies Corporation2$44
Beone Medicines USA, Inc.2$40
Eisai Inc.2$39
Macrogenics, Inc.2$38
Sobi, Inc2$37
EMD Serono, Inc.2$36
Agios Pharmaceuticals, Inc.2$35
Deciphera Pharmaceuticals Inc.2$34
Morphosys, US Inc.2$31
Geron Corporation2$31
Bristol Myers Squibb2$30
CTI Biopharma Corp.2$29
Jazz Pharmaceuticals Inc.2$28
Sanofi1$23
Azurity Pharmaceuticals, Inc.1$22
Springworks Therapeutics, Inc.1$21
Exelixis Inc.1$21
Tempus AI, Inc1$19
Puma Biotechnology, Inc.1$18
Immunocore Limited1$17
Ipsen Biopharmaceuticals, Inc1$17
Verastem, Inc.1$16
Axsome Therapeutics, Inc.1$15
AMAG Pharmaceuticals, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,590 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$38,299
Medicare patients
334
Services billed
900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib12$186,722
BrukinsaZanubrutinib12$171,165
IbrancePalbociclib11$155,483
EliquisApixaban130$143,370
ProcritEpoetin Alfa18$60,881
XareltoRivaroxaban44$48,434
Letrozole97$2,259
Anastrozole48$906
ValacyclovirValacyclovir Hcl22$859
Omeprazole54$526
Ondansetron Hcl25$253
Hydroxyurea12$225
Mometasone Furoate12$212
Gabapentin29$207
Prednisone41$182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$635$298,853141 claims
Lilly USA, LLCVerzenio$136$186,72212 claims
Beigene USA, Inc.Brukinsa$201$171,16512 claims
Johnson & JohnsonProcrit, Xarelto$753$109,31562 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.

Other adult health in Springfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →